poisar

Stocks · News reference

8-K filing — RenovoRx, Inc. (RNXT)

SEC EDGARAug 4, 2026, 8:10 PMSEC EDGAR

Filed: 2026-08-04 AccNo: 0001493152-26-035995 Size: 258 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
edgar
Observed
Aug 4, 2026, 8:10 PM
Checked
Aug 4, 2026, 8:10 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaAug 25, 2026, 12:36 PMBenzinga Newsdesk

    RenovoRx Announces Publication Of Sub-Study Data From Its Ongoing Phase III TIGeR-PaC Clinical Trial In The Journal Cancer Chemotherapy And Pharmacology; Data Show Trans-Arterial Micro-Perfusion-Mediated Delivery Concentrated Chemotherapy At The Tumor Site, Extracting ~51% Of Drug Locally Before It Entered The Bloodstream, Meaningfully Lowering Systemic Exposure

    RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared

    Read original at benzinga